Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies

Annals of the Rheumatic Diseases

Volumn 74, Issue 8, 2015, Pages 1621-1625

  Dees, Clara ^a   Beyer, Christian ^a   Distler, Alfiya ^a   Soare, Alina ^a,b,c   Zhang, Yun ^a   Palumbo Zerr, Katrin ^a   Distler, Oliver ^d   Schett, Georg ^a   Sandner, Peter ^e,f   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CANTACUZINO INSTITUTE   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e BAYER PHARMA AG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; GUANYLATE CYCLASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHODIESTERASE V INHIBITOR; RIOCIGUAT; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CLINICAL EFFECTIVENESS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; TREATMENT RESPONSE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; INBRED MOUSE STRAIN; PATHOLOGY; SCLERODERMA, SYSTEMIC; SKIN;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GUANYLATE CYCLASE; MICE; MICE, INBRED STRAINS; PHOSPHODIESTERASE 5 INHIBITORS; PYRAZOLES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SILDENAFIL CITRATE; SKIN;

EID: 84940023827     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206809     Document Type: Article

References (20)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 2012;81:533-59.
3. Evora PR, Evora PM, Celotto AC, et al. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets 2012;13:1207-14..
4. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
5. Beyer C, Zenzmaier C, Palumbo-Zerr K, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann Rheum Dis 2015;74:1408-16.
6. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
7. Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007;25:30-45.
8. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831-44.
9. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
10. Reich N, Tomcik M, Zerr P, et al. Jun. N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012;71:737-45.
11. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
12. Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012;120:2909-17.
13. Zerr P, Distler A, Palumbo-Zerr K, et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012;181:1672-80.
14. Lange F, Bajtner E, Rintisch C, et al. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis 2005;64:599-605.
15. Dees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis. Arthritis Rheum 2012;64:3006-15.
16. Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011;70:1304-10.
17. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785-9.
18. Masuyama H, Tsuruda T, Sekita Y, et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 2009;32:597-603.
19. Egemnazarov B, Sydykov A, Schermuly RT, et al. Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2009;296:L462-469.
20. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8.